KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Finished Goods (2016 - 2019)

Pfizer (PFE) has disclosed Finished Goods for 11 consecutive years, with $2.3 billion as the latest value for Q1 2019.

  • Quarterly Finished Goods fell 19.42% to $2.3 billion in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Mar 2019, down 19.42% year-over-year, with the annual reading at $2.3 billion for FY2018, 21.54% down from the prior year.
  • Finished Goods for Q1 2019 was $2.3 billion at Pfizer, up from $2.3 billion in the prior quarter.
  • The five-year high for Finished Goods was $2.9 billion in Q4 2017, with the low at $1.8 billion in Q2 2015.
  • Average Finished Goods over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2016.
  • The sharpest move saw Finished Goods fell 24.86% in 2015, then soared 49.89% in 2016.
  • Over 5 years, Finished Goods stood at $2.7 billion in 2015, then fell by 15.51% to $2.3 billion in 2016, then grew by 25.73% to $2.9 billion in 2017, then decreased by 21.54% to $2.3 billion in 2018, then rose by 1.11% to $2.3 billion in 2019.
  • According to Business Quant data, Finished Goods over the past three periods came in at $2.3 billion, $2.3 billion, and $2.6 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.